Medico Remedies Ltd. engages in the manufacture, supply, and exportation of pharmaceutical drugs. The company is headquartered in Thane, Maharashtra. The company went IPO on 2018-02-08. The company is engaged in the manufacturing of medicines including Diuretics, Antimalarials, NSAIDS Tablets, Antireterovirals, Anti-Ulcer Drugs and Antacids Tablets. The company has manufacturing and marketing capabilities in formulation with focus on anti-infective, Beta-Lactums, cephalosporins, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins, haematinics and other supplements. In addition, the Company also manufactures other drugs, such as non-steroidal anti-inflammatory drugs (NSAIDS), antihistaminic, anti-diabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments. Its products include Doxycycline Capsules, Zenof-400 (Ofloxacin Tablets 400mg), Azithromycin Tablets, Aciclovir Tablets, Cipta Tablets, Cotrimoxazole Tablets, Tos Syrup, Paediatric Co-Trimozole Oral, Med Reactin (Cyproheptadine), and Medivit Syrup.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.